PhotoDashboard
JBSA Photo Gallery
Air Force Lt. Col. Penny Vroman, Brooke Army Medical Center Nuclear Medicine Department chief, looks at scans of a patient with neuroendocrine tumors June 26, 2019 to see if the radiopharmaceutical drug is targeting the tumors. The use of lutetium Lu 177 dotatate, a radioactive medicine that binds itself to a specific part of certain tumor cells, was approved by the Food and Drug Administration in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, including foregut, midgut and hindgut neuroendocrine tumors in adults.
190626-A-SR136-1003.JPG Photo By: Lori Newman

JOINT BASE SAN ANTONIO-FORT SAM HOUSTON, Texas - Air Force Lt. Col. Penny Vroman, Brooke Army Medical Center Nuclear Medicine Department chief, looks at scans of a patient with neuroendocrine tumors June 26, 2019 to see if the radiopharmaceutical drug is targeting the tumors. The use of lutetium Lu 177 dotatate, a radioactive medicine that binds itself to a specific part of certain tumor cells, was approved by the Food and Drug Administration in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, including foregut, midgut and hindgut neuroendocrine tumors in adults.


DOWNLOAD PHOTO (0.83 MB)


This photograph is considered public domain and has been cleared for release. If you would like to republish please give the photographer appropriate credit. Further, any commercial or non-commercial use of this photograph or any other DoD image must be made in compliance with guidance found at http://www.dimoc.mil/resources/limitations.html , which pertains to intellectual property restrictions (e.g., copyright and trademark, including the use of official emblems, insignia, names and slogans), warnings regarding use of images of identifiable personnel, appearance of endorsement, and related matters.



Back to Gallery